ArticleScientific reports2025
Characteristics of the gut microbiota in patients with advanced non-small cell lung cancer who responded to immune checkpoint inhibitors.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Review
- Smoking-associated modulation of gut microbiota shapes response to immune checkpoint inhibitors in non-small cell lung cancer.Cancer immunology, immunotherapy : CII · 2026Article
- Microbial Influence on Immune Checkpoint Inhibitor Therapy in Non-Small Cell Carcinoma: The Gut-Lung-Immune Axis.Cancers · 2026Review
- Harnessing Gut Microbiota to Enhance Immunotherapy in NSCLC: From Mechanisms to Translational Applications.Cancer medicine · 2026Review
- Charting the blueprint: a bibliometric analysis reveals future strategies in lung cancer targeted therapy (2003-2025).Journal of thoracic disease · 2026Article
- Harnessing the Gut Microbiota to Improve Cancer Immunotherapy: Focus on Lung Cancer.Immune network · 2026Review
- Microbial metabolites and the gut-lung axis in non-small cell lung cancer immunotherapy: evidence boundaries and translational implications.Frontiers in medicine · 2026Review
- Microbiome as a prediction of immunotherapy response in lung cancer.Frontiers in immunology · 2026Review
- Leveraging beneficial microbiome-immune interactions via probiotic use in cancer immunotherapy.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the introduction of immune checkpoint inhibitors (ICIs) in the treatment of lung cancer, the number of deaths from lung cancer remains high, and further improvements in response rates are necessary. Recently, the gut microbiota has been reported to be involved in the therapeutic effects of ICIs; however, only a few studies have examined patients with lung cancer in this context. In the current study, we aimed to explore the association between the gut microbiota before therapy and the efficacy of ICIs in patients with advanced non-small cell lung cancer (NSCLC). The a-diversity of the intestinal microbiota in patients who responded to ICI treatment (responders) was significantly higher than that in those who did not respond to ICIs (non-responders). Additionally, the abundance of Bifidobacteriaceae was significantly higher in the responders than in the non-responders. Furthermore, patients with a high abundance of Bifidobacteriaceae had significantly longer overall survival than those with a low abundance. Counts of Levilactobacillus brevis were significantly higher in responders than in non-responders. Our findings suggest that a higher diversity of the gut microbiota and an abundance of Bifidobacterium and/or L. brevis are distinctive features of the microbiota in patients with NSCLC who respond to ICI treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.